Vigil Neuroscience, Inc.
VIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | -$0 | -$0 | -$1 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $62 | $61 | $47 | $32 |
| G&A Expenses | $27 | $28 | $21 | $10 |
| SG&A Expenses | $27 | $28 | $21 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $89 | $89 | $69 | $42 |
| Operating Income | -$90 | -$89 | -$69 | -$42 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $6 | $1 | -$1 |
| Pre-Tax Income | -$84 | -$83 | -$68 | -$43 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$84 | -$83 | -$68 | -$43 |
| % Margin | – | – | – | – |
| EPS | -2.07 | -2.13 | -2.16 | -1.57 |
| % Growth | 2.8% | 1.4% | -37.6% | – |
| EPS Diluted | -2.07 | -2.13 | -2.16 | -1.57 |
| Weighted Avg Shares Out | 41 | 39 | 32 | 27 |
| Weighted Avg Shares Out Dil | 41 | 39 | 32 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$84 | -$88 | -$68 | -$42 |
| % Margin | – | – | – | – |